Foren & Soziale Netzwerke zur EXAGEN Aktie

 

Exagen Inc. has been on a wild ride, and while it had a strong rally last year, the current reality is a significant pullback . From the November highs of around $12.00, we've seen a steep 50% correction down to the $6.30 level. For a momentum trader, the trend is broken, but for a value hunter, this deep retracement might be offering a discount on a growing business, if it can find a floor and looking at the price actions and indicators this might be a good chance this is it. Fundamentally, the story is evolving beyond just standard lab tests. Exagen is increasingly integrating Advanced Machine Learning and Generative AI into their research pipeline to discover new autoimmune biomarkers and streamline clinical trials. That tech-forward approach is backing their solid 37.9% revenue growth , suggesting the business is expanding even if the share price has taken a beating. Technically, this is a "wait and see" setup. Price is currently still well below both its 50-day and 200-day SMAs, confirming the do